{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:42:52Z","timestamp":1772134972822,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41443-023-00749-7","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:03:38Z","timestamp":1692950618000},"page":"581-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insurance approval rates for collagenase clostridium histolyticum prior to discontinuation: a Canada-wide analysis"],"prefix":"10.1038","volume":"36","author":[{"given":"David","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Shiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-7535","authenticated-orcid":false,"given":"Dhiraj S.","family":"Bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Southall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9700-0805","authenticated-orcid":false,"given":"Ruben","family":"Blachman-Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Flannigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2748-6720","authenticated-orcid":false,"given":"Premal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"749_CR1","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1097\/01.ju.0000127744.18878.f1","volume":"171","author":"JP Mulhall","year":"2004","unstructured":"Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie\u2019s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350\u20133.","journal-title":"J Urol"},{"key":"749_CR2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/01.ju.0000053800.62741.fe","volume":"169","author":"SS Gholami","year":"2003","unstructured":"Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie\u2019s disease: a review. J Urol. 2003;169:1234\u201341.","journal-title":"J Urol"},{"key":"749_CR3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","volume":"168","author":"A Kadioglu","year":"2002","unstructured":"Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie\u2019s disease. J Urol. 2002;168:1075\u20139.","journal-title":"J Urol"},{"key":"749_CR4","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie\u2019s disease. J Urol. 2006;175:2115\u20138.","journal-title":"J Urol"},{"key":"749_CR5","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.5489\/cuaj.5255","volume":"12","author":"AJ Bella","year":"2018","unstructured":"Bella AJ, Lee JC, Grober ED, Carrier S, Benard F, Brock GB. 2018 Canadian Urological Association guideline for Peyronie\u2019s disease and congenital penile curvature. Can Urol Assoc J. 2018;12:E197\u2013209.","journal-title":"Can Urol Assoc J"},{"key":"749_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie\u2019s disease: AUA guideline. J Urol. 2015;194:745\u201353.","journal-title":"J Urol"},{"key":"749_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol"},{"key":"749_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/JU.0000000000000032","volume":"201","author":"WJG Hellstrom","year":"2019","unstructured":"Hellstrom WJG, Tue Nguyen HM, Alzweri L, Chung A, Virasoro R, Tapscott A, et al. Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with Peyronie\u2019s disease: results of a multi-institutional analysis. J Urol. 2019;201:777\u201382.","journal-title":"J Urol"},{"key":"749_CR9","unstructured":"Paladin Labs Inc. Healthcare Professional Information regarding discontinuation of XIAFLEX\u00ae. 2020. https:\/\/www.dupuytrencanada.ca\/DATA\/MEDIA\/2022\/10\/Xiaflex_Discontinuation_Notice_04302020.pdf."},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41443-021-00458-z","volume":"34","author":"U Mann","year":"2021","unstructured":"Mann U, Shiff B, Jain K, Flannigan R, Elterman D, Patel P. Canadian provider perspectives on collagenase clostridium histolyticum for the treatment of Peyronie\u2019s disease and the impact of its discontinuation. Int J Impot Res. 2021;34:599\u2013602.","journal-title":"Int J Impot Res"},{"key":"749_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.urpr.2016.04.005","volume":"4","author":"BH Cordon","year":"2017","unstructured":"Cordon BH, Hofer MD, Hutchinson RC, Broderick GA, Lotan Y, Morey AF. Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie\u2019s disease deformities. Urol Pract. 2017;4:118\u201325.","journal-title":"Urol Pract"},{"key":"749_CR12","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/andr.12830","volume":"8","author":"N Harvey","year":"2020","unstructured":"Harvey N, Pearce I. At what cost is collagenase clostridium histolyticum viable for treating Peyronie\u2019s disease in a public healthcare system? Andrology. 2020;8:1304\u201311.","journal-title":"Andrology"},{"key":"749_CR13","doi-asserted-by":"publisher","unstructured":"Wymer K, Hebert K, Kohler T, Trost LW. MP65-05 Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in the treatment of Peyronie\u2019s disease. J Urol. 2019;201. https:\/\/doi.org\/10.1097\/01.ju.0000556917.78697.44.","DOI":"10.1097\/01.ju.0000556917.78697.44"},{"key":"749_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41443-020-0297-6","volume":"33","author":"S Gamidov","year":"2021","unstructured":"Gamidov S, Shatylko T, Gasanov N, Scherbakov D, Li K, Sukhikh G. Long-term outcomes of surgery for Peyronie\u2019s disease: focus on patient satisfaction. Int J Impot Res. 2021;33:332\u20138.","journal-title":"Int J Impot Res"},{"key":"749_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","volume":"16","author":"M Alom","year":"2019","unstructured":"Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie\u2019s disease. J Sex Med. 2019;16:891\u2013900.","journal-title":"J Sex Med"},{"key":"749_CR16","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1111\/j.1743-6109.2011.02299.x","volume":"8","author":"S Flores","year":"2011","unstructured":"Flores S, Choi J, Alex B, Mulhall JP. Erectile dysfunction after plaque incision and grafting: Short-term assessment of incidence and predictors. J Sex Med. 2011;8:2031\u20137.","journal-title":"J Sex Med"},{"key":"749_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1743-6109.2010.02102.x","volume":"8","author":"E Chung","year":"2011","unstructured":"Chung E, Clendinning E, Lessard L, Brock G. Five-year follow-up of Peyronie\u2019s graft surgery: outcomes and patient satisfaction. J Sex Med. 2011;8:594\u2013600.","journal-title":"J Sex Med"},{"key":"749_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jsxm.2021.02.002","volume":"18","author":"N Punjani","year":"2021","unstructured":"Punjani N, Nascimento B, Salter C, Miranda E, Terrier J, Taniguchi H, et al. Predictors of depression in men with Peyronie\u2019s disease seeking evaluation. J Sex Med. 2021;18:783\u20138.","journal-title":"J Sex Med"},{"key":"749_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","volume":"10","author":"CJ Nelson","year":"2013","unstructured":"Nelson CJ, Mulhall JP. Psychological impact of Peyronie\u2019s disease: a review. J Sex Med. 2013;10:653\u201360.","journal-title":"J Sex Med"},{"key":"749_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","volume":"41","author":"M Shirazi","year":"2009","unstructured":"Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41:467\u201371.","journal-title":"Int Urol Nephrol"},{"key":"749_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.eururo.2018.07.005","volume":"74","author":"GI Russo","year":"2018","unstructured":"Russo GI, Milenkovic U, Hellstrom W, Levine LA, Ralph D, Albersen M. Clinical efficacy of injection and mechanical therapy for Peyronie\u2019s disease: a systematic review of the literature. Eur Urol. 2018;74:767\u201381.","journal-title":"Eur Urol"},{"key":"749_CR22","doi-asserted-by":"publisher","first-page":"e0150157","DOI":"10.1371\/journal.pone.0150157","volume":"11","author":"M Stuntz","year":"2016","unstructured":"Stuntz M, Perlaky A, Des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie\u2019s disease in the United States: a population-based study. PLoS One. 2016;11:e0150157.","journal-title":"PLoS One"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00749-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00749-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00749-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T05:27:15Z","timestamp":1725514035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00749-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1038\/s41443-023-00749-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2864864\/v1","asserted-by":"object"}]},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RF has received speaking honoraria and an education grant from Boston Scientific and speaking honoraria from Paladin Labs. PP is a consultant for Boston Scientific. The remaining authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Research ethics board approval as per TCPS2 was not required in this study as all data from BioScript Solutions is previously anonymized and no confidential patient information was accessible.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}